Poveda, A.Martinez, V.Serrano, C.Sevilla, I.Lecumberri, M. J.de Beveridge, R. D.Estival, A.Vicente, D.Rubio, J.Martin-Broto, J.2023-02-122023-02-122016-12-011699-048Xhttp://hdl.handle.net/10668/18651Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, and this disease has served as a paradigmatic model for successful rational development of targeted therapies. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. The Spanish Society of Medical Oncology (SEOM) guidelines provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.enAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/GISTImatinibSunitinibRegorafenibStromal tumorsAdjuvant imatinibRandomized-trialPhase-iiiFollow-upKinaseRiskMulticenterSensitivityRecurrenceGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHumansPractice Guidelines as TopicSpainresearch articleopen access10.1007/s12094-016-1579-91699-3055https://link.springer.com/content/pdf/10.1007%2Fs12094-016-1579-9.pdf389970300009